drugset / Trial / NCT01656434
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study was to assess the contraceptive efficacy of a nomegestrol acetate + 17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active American women at risk for pregnancy. Vaginal bleeding patterns of women taking NOMAC-E2 were assessed and compared to those of women taking a norethisterone acetate + ethinyl estradiol (NETA-EE) COC. The safety of NOMAC-E2 was also assessed. Participants were randomized to receive either NOMAC-E2 or NETA-EE in a 3:1 ratio. As of Amendment 1 (which increased the sample size of the NOMAC-E2 group), the randomization ratio was adapted accordingly for participants randomized after the sample size increase.
Timeline
- Start
- 2012-11-02
- Primary completion
- 2014-02-12
- Completion
- 2014-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 17ß-estradiol | Unknown | 1.5 mg | Oral |
| Subject | Nomegestrol Acetate | Small molecule | 2.5 mg | Oral |
| Comparator | Norethindrone | Unknown | 1 mg | Oral |
| Comparator | ethinyl estradiol | Small molecule | 10 ug | Oral |
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 75 mg | — |
Indications
No indication recorded.